ESSA Pharma Inc.

NasdaqCM:EPIX

Sector

🏥 Health Care

Industries

🔬 Clinical Trials

🧬 Biotechnology

Location

Canada

Market Cap

USD 76.79 M

Share Price

USD 1.73

Avg Daily Volume

162,368

Change (1 day)

2.37%

Change (1 year)

-65.26%

Change (YTD)

-3.35%

ESSA Pharma Inc. EBITDA for the Trailing 12 Months (TTM) ending March 31, 2025

ESSA Pharma Inc. EBITDA is NA for the Trailing 12 Months (TTM) ending March 31, 2025. EBITDA means earnings before interest, taxes, depreciation, and amortization, which measures a company's operating performance by excluding non-operating expenses.

ESSA Pharma Inc. EBITDA for the Trailing 12 Months (TTM) ending March 31, 2024 was USD -27.63 M, a -4.50% change year over year.
ESSA Pharma Inc. EBITDA for the Trailing 12 Months (TTM) ending March 31, 2023 was USD -28.93 M, a -22.06% change year over year.
ESSA Pharma Inc. EBITDA for the Trailing 12 Months (TTM) ending March 31, 2022 was USD -37.12 M, a 29.88% change year over year.
ESSA Pharma Inc. EBITDA for the Trailing 12 Months (TTM) ending March 31, 2021 was USD -28.58 M, a 59.64% change year over year.

Quarterly
Annual
TTM

From:

To:

Zoom:

Key data

Date	EBITDA	Net Income	EPS (Diluted)	Shares (Diluted, Weighted)

NasdaqCM: EPIX

ESSA Pharma Inc.

CEO	Dr. David Ross Parkinson M.D.
IPO Date	March 13, 2015
Location	Canada
Headquarters	999 West Broadway
Employees	35
Sector	🏥 Health Care
Industries Clinical Trials 🧬 Biotechnology

Description

ESSA Pharma Inc., a clinical stage pharmaceutical company, focuses on developing novel and proprietary therapies for the treatment of prostate cancer. It develops EPI-7386, an oral candidate that is in a Phase I clinical study for the treatment of patients with metastatic castration-resistant prostate cancer. The company has collaboration agreements with Caris Life Sciences, Inc.; Bayer Consumer Care AG; Janssen Research & Development, LLC; and Astellas Pharma Inc. ESSA Pharma Inc. was incorporated in 2009 and is headquartered in Vancouver, Canada.